RPL22 and cancer: Overall, the TP53-F2-344* cluster was the most prevalent in pan-cancer analysis, appearing in 20 different cancer types and representing approximately 1.0% (0.20%-3.5%) frequency of all the cases, followed by RPL22-F2-19* at 0.91%, RNF43-F2-699* at 0.87% and SETD1B-F2-34* at 0.82% (Figure 1D).